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Abstract 
Although kidney disease impacts on fertility, increasing numbers of pregnancies are 
reported in women on dialysis. Despite a trend of increasing live birth rates over 
recent decades, pregnancies on dialysis remain high risk, with increased rates of 
adverse pregnancy outcomes including pregnancy loss, pre-eclampsia, pre-term 
delivery, low birth weight and the requirement for neonatal intensive care.  This 
article describes the prevalence of dialysis and pregnancy in women of childbearing 
age, with relevant information regarding the effects of end-stage renal disease on 
fertility in women. Pregnancy outcomes for women on dialysis are summarised, 
including their association with dialysis intensity. A guide to pre-pregnancy 
counselling, and the management of pregnancy on dialysis is provided. Factors that 
inform the decision to commence dialysis in pregnancy are examined. The 
advantages and disadvantages of peritoneal dialysis in pregnancy are discussed.   
 
KEY WORDS: renal dialysis, peritoneal dialysis, renal replacement therapy, 
pregnancy, reproduction.  
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Dialysis and pregnancy in women of childbearing age  
The number of women of childbearing age receiving dialysis varies according to 
healthcare provision and renal disease incidence. In the United Kingdom, the 
prevalence of dialysis in women of childbearing age (18-45 years) is 150 women per 
million population, with the most prevalent underlying diagnoses being 
glomerulonephritis and diabetic nephropathy [1,2]. For women receiving dialysis, 
reproductive healthcare options and outcomes are dictated by the effect of end-
stage renal disease on pregnancy.  
 
The first report of a live birth in a woman receiving haemodialysis was published in 
1971 [3]. Since then, increasing rates of pregnancy in women on dialysis are 
reported. The Australian and New Zealand Dialysis and Transplantation (ANZDATA) 
registry reported pregnancy rates of 0.54 per 1000 person years from 1976-1985, 
0.67 from 1986-1995, and 3.3 from 1996-2008 [4]. Similarly, a systematic review of 
dialysis in pregnancy identified 90 cases between 2000 and 2008, compared to 584 
pregnancies in the years 2008-2014 [5]. Although publication bias cannot be 
excluded, a six-fold increase in literature is strongly suggestive of an increasing 
incidence of pregnancy in women on dialysis. Improved obstetric surveillance, blood 
pressure control, the availability of erythropoietin stimulating agents, a change in 
the clinician-approach to pregnancy in chronic kidney disease, and the use of 
intensive dialysis regimens can all be hypothesised to be important contributing 
factors. However, the overall incidence of pregnancy in women receiving dialysis 
remains low and is estimated to be 1% of that in the population [6, 7].   
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Fertility and dialysis 
Impaired renal function impacts that hypothalamic-pituitary-ovarian axis leading to 
an inverse relationship between glomerular filtration and fertility [7]. Ovulation is 
triggered by a surge in the concentration of leutenising hormone at the mid-point of 
the menstrual cycle, driven by the positive feedback of oestrogen to the 
hypothalamus-pituitary. In women with advanced chronic kidney disease, oestrogen 
concentrations are low leading to negative feedback to the hypothalamus, and 
although leutenising hormone (LH) concentrations are increased [8], there is a loss of 
variability and the mid-cycle surge [9] and ovulation fail to occur. In addition, there is 
impaired renal clearance of prolactin [9,10], which mimics the physiological effect of 
breast-feeding and confers additional suppression of ovulation. Treatment with 
cyclophosphamide, which is used in the treatment of rapidly progressive glomerular 
disease is known to be gonadotoxic and may contribute to infertility.  Small cohort 
studies show that 42% of women on dialysis have a regular menstrual cycle, 
compared to 75% prior to the start of dialysis [11], and 37-59% of women on 
hameodialysis are amenorrhoeic [11,12]. Importantly, kidney disease is also 
associated with non-mechanistic sexual dysfunction including reduced libido, 
dyspareunia, negative body image and depression, even before the need for dialysis 
arises [13,14].   
 
Pregnancy rates in women receiving peritoneal dialysis are less well described in 
published literature, but appear lower than rates on haemodialysis. ANZDATA shows 
pregnancy rates of 1.06 pregnancies per 1000 patient years in women on peritoneal 
dialysis, which is significantly less than the haemodialysis rate of 2.54 [4]. This has 
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led to conjecture that the use of intraperitoneal fluid may be associated with 
mechanical or inflammatory effects on the fallopian tube and/or uterus, in addition 
to the endocrine effects of renal impairment.   
 
Although end-stage renal disease impairs fertility, it is not in itself a reliable form of 
contraception and unplanned pregnancies do occur. There is emerging evidence that 
this may be particularly relevant for women receiving an increased number of hours 
of dialysis. Increasing haemodialysis provision from 16.5 to 28 hours per week in a 
small cohort of seven women was associated return of menses in 2 out of 3 
previously amenorrhoiec women, and intensifying treatment to 36 hours of dialysis 
per week (from 12 hours) in a single centre led to conception rates of 15.6% (7 out of 
45 women), which is 10 times greater than that reported by national registries 
[15,16].  
 
The provision of safe and effective contraception is essential for women on dialysis 
who do not wish to conceive. However, contraceptive advice and provision for 
women on dialysis remains inadequate for women with CKD, including those on 
dialysis [7]. There is limited guidance on contraception for women on dialysis, and 
safety data [17] are generalised from other high-risk groups Effectiveness must 
consider the failure rate with ‘typical-use’ as discrepancies exist compared to 
‘prefect-use’ [18]. For example, the ‘typical-use’ of condoms leads to 18-21% of 
couples experiencing an unintended pregnancy in the first year of use, which means 
they are an unacceptable long-term option for women who wish to avoid pregnancy. 
Progesterone based methods avoid the risks associated with oestrogen use; namely 
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hypertension, vascular disease, lupus flare, thromboembolism and cervical cancer. 
Progesterone only methods are therefore considered safe for women on dialysis [19] 
and include the progesterone-only pill, the intra-uterine system (Mirena) and the 
progesterone implant (Nexplanon), with typical use failure rates of 9%, 0.5% and 
0.02% respectively [18]. The copper coil is a safe and effective non-hormonal based 
method. Progesterone-only emergency contraception can be provided to prevent 
pregnancy up to 72 hours after unprotected sexual intercourse.  
 
Pregnancy outcomes on haemodialysis 
Population studies [20], large cohorts [21], and meta-analysis [22] show that chronic 
kidney disease confers an increased risk of adverse pregnancy outcomes including 
pregnancy loss, pre-eclampsia, pre-term delivery, small-for-gestational-age babies, 
admission to neonatal intensive care and perinatal death. Absolute risk rates vary 
between studies and are affected by cohort size, the timing and method by which 
renal function is measured, and clinician thresholds for iatrogenic delivery and 
intensive care admission. However, a consistent finding is the increment in risk with 
worsening CKD stage and the highest rates of adverse outcomes for women on 
dialysis. 
 
Rates of adverse pregnancy outcomes for women on dialysis are shown in Table 1.  
This table demonstrates an increase in the live birth rate of babies born to women 
on dialysis over the last 30 years, although a high prevalence of pre-term delivery 
and low-birth weight babies remain consistent findings. Rates of pre-eclampsia are 
heterogeneous. The difficulty in making a diagnosis of superimposed pre-eclampsia 
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in the clinical context of pre-existing hypertension and/or proteinuria/ anuria is a 
likely contributing factor (see: Obstetric management).  
 
Numerous cohort studies demonstrate a trend of improved pregnancy outcomes 
with longer dialysis time in pregnancy [23–30]. This is most convincingly shown in a 
Canadian cohort of 22 women with established end-stage renal disease receiving 
43±6 hours of dialysis per week during pregnancy. This was associated with a 
significantly higher birth rate (83% versus 53%) and increased gestational age (36 
versus 27 weeks) compared to the provision of 17±5 hours of dialysis per week [28]. 
Meta-analysis of data from 2000-2014 showed that dialysis frequency and dialysis 
duration show an inverse correlation with rates of preterm delivery and small for 
gestational age infants [5], although data heterogeneity prevents stratification by 
other potentially important factors including maternal age, renal disease aetiology 
and the level of residual renal function. A recent large Brazilian case series of women 
receiving haemodialysis during pregnancy between 2000 and 2017 included 47 
women with established end-stage renal disease and 46 women with new dialysis 
requirements in pregnancy [30]. Multivariable modelling of the data showed that 
midweek blood urea nitrogen was significantly associated with gestation adjusted 
fetal weight, although the development of pre-eclampsia remained the most 
important factor in predicting adverse pregnancy outcome.  
 
Pre-pregnancy counselling for women on dialysis 
Pre-pregnancy counselling is advocated for all women with a pre-existing medical 
condition given the identification of maternal mortality in women who do not 
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receive pre-pregnancy advice [31].  Although maternal risk in CKD is comparable to 
the general population, there is a significantly increased risk to the babies born to 
women on dialysis including preterm delivery, small for gestational age infants, and 
an 18% risk of perinatal death [5]. However, CKD does not remove the innate longing 
to have a child and the patient experience of physicians’ warnings against pregnancy 
in CKD can be traumatic [32]. Neither CKD nor the need for dialysis should negate 
the autonomous decision to undertake a pregnancy, but autonomy is only possible 
with a full understanding of the implications of kidney disease for pregnancy and 
therefore the provision of expert, individualised pre-pregnancy counselling is 
essential. The challenges of undertaking a pregnancy on dialysis for women and their 
care-givers, as well as the very real possibility of parenting a small, sick neonate must 
be effectively communicated.  
 
The risks of pregnancy following successful kidney transplantation are lower that 
those on dialysis. The possibility of a lower-risk pregnancy in the future should 
therefore be considered, although this is dependent upon the likely timing of 
transplantation within the window of child-bearing age, graft stability at >1 year and 
immunosuppressive regimens compatible with pregnancy. Parenthood in the 
absence of pregnancy can be achieved by surrogacy and adoption although the 
validity of these options for women on dialysis depend upon legal, ethical, and 
cultural factors, which vary across the world. In the UK, adoption is not a service for 
infertile or high-risk women, but a service for children, who often have complex 
parenting needs. It requires a detailed approval process including consideration of 
the time commitment of dialysis, the capacity of partners and family to provide 
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parenting support in the event of deteriorating maternal heath, and prognosis within 
the life of the child.  
 
Pre-pregnancy counselling requires optimisation of maternal health in advance of 
pregnancy. Relevant modifiable risk factors are shown in Table 2. Given the 
association between longer dialysis time and improved neonatal outcome (see: 
Pregnancy outcomes on haemodialysis) and concern regarding intensification of 
peritoneal dialysis (see: Peritoneal dialysis), a plan should be made for increased 
provision of haemodialysis in the event of pregnancy.  
 
The management of pregnancy in women established on haemodialysis 
Published data on dialysis in pregnancy is limited by cohort size and clinical 
heterogeneity. Randomised control trial evidence is unlikely to inform the 
management of women on dialysis in pregnancy due to both the rarity of the 
condition and the ethical difficulties in randomisation given a perceived lack of 
clinical equipoise, with clinicians uncomfortable with the provision of less than 6-
times-weekly dialysis for women with established renal failure in pregnancy [33]. 
Clinical guidance is therefore based on low-moderate levels of evidence, 
generalisation of evidence from non-CKD cohorts, and expert consensus. However, 
levels of evidence defined by traditional hierarchies should not lead to presumptions 
about quality. Clinical experience and multidisciplinary working are difficult to 
quantify for the purposes of intervention research but such factors are repeatedly 
hypothesised to contribute to improved pregnancy outcomes [16,28,30]. Antenatal 
care for women on dialysis should take place within an expert, collaborative 
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multidisciplinary team including obstetricians, nephrologists, fetal medicine 
specialists, neonatologists, nurses, midwifes and dieticians; acknowledging the 
essential the support that is provided by partners and family. The clinical value of 
expert consensus statements from such groups should not be underestimated.  
 
Diagnosing pregnancy 
Diagnosis of pregnancy is difficult in end stage renal disease due to the fact that 
irregular menstrual cycles and amenorrhea are common in women on dialysis (see: 
Fertility and dialysis), and urine volumes may be insufficient for standard pregnancy 
tests.  The kidney plays a key role in the metabolism of beta-human chorionic 
gonadotrophin (β-HCG). Reduced parenchymal and excretory function is thought to 
contribute to the detection of elevated serum concentrations β-HCG in 8-16% of 
non-pregnant women with CKD [34,35].  The sensitivity and specificity of a relative 
rise in β-HCG for the diagnosis of pregnancy in CKD remain unknown. Verification 
and dating of pregnancy by ultrasound imaging is recommended [36].  
 
Haemodialysis management for established end-stage renal failure in pregnancy 
Intensive (>36 h/week) haemodialysis in pregnancy facilitates ‘gentle’ excess fluid 
removal with less variation in intra-dialytic blood pressure, better blood pressure 
control and better fetal outcomes compared to standard dialysis (≤20 h/week) [15, 
28]. A continuous association between increased dialysis provision and improved 
fetal outcome is shown at >20h/week [25,26,29] and >36 hours per week [28]. Expert 
consensus from Italy suggests 36 hours as a minimum target for haemodialysis 
provision in pregnancy [36].  
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An alternative approach uses the serum urea concentration to guide the 
intensification of dialysis. Retrospective survey data suggests better pregnancy 
outcome at urea thresholds of <21mmol/L [37] and <17.9mmol/L [29]. A large 
contemporary cohort of 93 pregnancies showed that a midweek pre-dialysis blood-
urea-nitrogen >35mg/dl (urea >12.5mmol/L) had a sensitivity of 88% and an odds 
ratio of 6.4 (CI: 1.4-30.0) for adverse fetal outcome [30]. With increasing recognition 
of the value of intensive dialysis in pregnancy, recommended targets for pre-dialysis 
urea concentration in pregnancy have shown a progressive decline from <17mmol/L 
[36], to 10-15mmol/L [16], to <12.5mmol/L [19]. The use of a target serum urea 
concentration potential facilitates individualisation of dialysis intensification in 
pregnancy, allowing for adjustment according to residual renal function. This is likely 
to be most relevant to women newly commenced on dialysis (see: New 
haemodialysis in pregnancy).  
 
Establishing an appropriate dry-weight for dialysis requires expert clinical 
examination including an appreciation of the normal haemodynamic changes of 
pregnancy (‘a hyperdynamic hyperhydrated state’[36]), aiming for a post-dialysis 
blood pressure <140/90mmHg whilst avoiding intra-dialytic hypotension 
(<120/70mmHg) [16]. Weight gain due to pregnancy is estimated to be 300-
500g/week during the second and third trimesters and should be accommodated 
appropriately in dialysis weight targets [36,38]. Low molecular weight and 
unfractionated heparins can be safely used in pregnancy to prevent clotting of the 
haemodialysis circuit, according to non-pregnant protocols. For women receiving 
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intensified daily dialysis regimens in pregnancy there may be a need to use higher 
dialysate concentrations of potassium (3mEq/L), calcium (1.5mmol/L), and 
phosphate [16]. Serum magnesium concentration may also fall with intensive dialysis 
and oral supplementation may be required given the recognised association of low 
magnesium levels with hypertensive disorders of pregnancy [39] and uterine 
contraction [36].  
 
Erythropoietin concentrations approximately double in physiological pregnancy in 
the absence of CKD [40] so an increase in synthetic erythropoietin requirements 
should be anticipated for women on dialysis in pregnancy. Iron deficiency is common 
in pregnancy and the safe use of intravenous iron sucrose [41, 42,43] and dextran 
[44] are described in pregnancy. Vitamin D deficiency should be corrected for all 
pregnant women, including the use of activated analogues for women on dialysis. 
Calcimimetic drugs are discontinued given the limited data on their use in 
pregnancy. Depending on the amount of dialysis provided in pregnancy, it may be 
possible to discontinue phosphate binders. If phosphate binders are indicated, 
calcium is safe for use in pregnancy, although sevelamer should be avoided due to 
animal evidence of impaired ossification of the fetal skeleton.  
 
Obstetric management  
All women who require, or who may require, dialysis in pregnancy have a high risk 
for adverse pregnancy outcomes and should be referred in early pregnancy for 
consultant-led obstetric care. Recommendations for the obstetric management of 
pregnant women on dialysis are based on case series [15, 28], expert opinion [16, 36, 
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45] and generalisation of good quality evidence from other high-risk groups [46, 47]. 
The obstetric management of women on dialysis is detailed in Table 3. 
 
Meta-analysis demonstrates that women with CKD have a ten-fold higher risk for the 
development of pre-eclampsia compared to women with normal renal function [22] 
and statistical modelling of retrospective cohort data shows that the development of 
pre-eclampsia is the most important factor in predicting adverse pregnancy outcome 
in women on dialysis [30].  However, diagnosis of pre-eclampsia is complicated in 
women with CKD, including those on dialysis. A diagnosis of pre-eclampsia is based 
on de novo development of hypertension after 20 weeks gestation in association 
with proteinuria and/or evidence of systemic disease (maternal acute kidney injury, 
liver dysfunction, neurological features, haemolysis, thrombocytopenia, or fetal 
growth restriction) [48]. Such definitions are rendered redundant for the majority of 
women on dialysis who may have chronic hypertension, variation in blood pressure 
according to fluid state, pre-existing proteinuria and/or anuria. Standardised 
definitions of superimposed pre-eclampsia in women with CKD do not exist. Regular, 
expert surveillance of fetal growth and well-being, and clinical assessment for 
systemic signs and symptoms are mandatory for pregnant women on dialysis.  
 
Fetal surveillance in women on dialysis involves regular assessment of fetal growth 
after 20 weeks gestation in conjunction with Doppler ultrasound assessments of flow 
in uterine and umbilical arteries. A small prospective study of 15 women with 
hypertension and/or CKD has demonstrated that an increased vascular resistance in 
the uterine artery at 20-24 weeks gestation has 100% specificity for the 
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development of superimposed pre-eclampsia, although this requires validation in a 
larger cohort, including women on dialysis [49].  Progressive changes in the 
waveform in the umbilical artery are used in the assessment of fetal distress and 
inform decisions regarding iatrogenic preterm delivery. Data from 61 women with 
CKD suggest that the combination of uterine and umbilical flow patterns can be used 
to distinguish CKD, which is associated with normal flow, from superimposed pre-
eclampsia where flow velocity waveforms are abnormal [50]. 
 
There is now emerging evidence for the use of angiogenic (placental growth factor, 
PlGF) and antiangiogenic (soluble fms-like tyrosine kinase, sFlt-1) biomarkers in the 
prediction and diagnosis of pre-eclampsia. Low circulating concentrations of PlGF 
and/or high concentrations of sFlt-1 have been shown to be useful tools for the 
prediction of pre-eclampsia [51] and the need for delivery [52] in the general 
obstetric population. Similar biomarker profiles are reported in women with chronic 
hypertension and CKD [49], and in a case report of a woman receiving dialysis in 
pregnancy [53].  Rolfo et al. was able to demonstrate distinction of CKD from pre-
eclampsia using the ratio of s-FLT:PlGF, although superimposed pre-eclampsia in 
women with CKD was not examined [54]. Further data on the predictive and 
diagnostic use of PlGF and s-Flt1 in women with advanced CKD are awaited.  
 
New haemodialysis in pregnancy  
Published literature from 1985-2007 shows that women with a pre-pregnancy 
creatinine >180µmol/L have a 70% chance of a decline in renal function during 
pregnancy [55]. Contemporary cohorts show the risk of progression to dialysis in 
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pregnancy is 20-50% for women with a pre-pregnancy eGFR <30ml/min/1.73m
2
 
[21,56]. In the event of such a decline in renal function in pregnancy, the clinical 
dilemma of when to start dialysis in pregnancy remains.  
 
Indications for commencement of dialysis in the non-pregnant population include 
symptomatic uraemia, evidence of protein-energy wasting, and the inability to safely 
manage metabolic abnormalities and/or volume overload with medical therapy [33]. 
However, in the context of pregnancy, the fetotoxicity of urea is likely to precede 
any maternal indications for dialysis, although the absolute level of urea at which the 
provision of dialysis improves pregnancy outcome remains unknown. Studies that 
have examined the level of urea at which fetal harm occurs are largely historical. In 
1963, there were no surviving infants in a cohort of women with urea >21.4mmol/L 
[57], and in 1968 there 50% infant survival rate when maternal urea was 
>17.9mmol/L [58], although such outcomes also reflect standards of obstetric, renal 
and neonatal care from 50 years ago. Current practice remains variable from 
automatic commencement of dialysis when urea is >17mmol/L [59], to the 
consideration of dialysis only for women with progressive loss of renal function and a 
urea consistently >20mmol/L [16]. 
 
Residual renal function is hypothesised to contribute to the better outcomes seen in 
women commencing dialysis during pregnancy, compared to women established on 
dialysis prior to pregnancy [60]. As residual function confers some filtration capacity, 
intensification of dialysis may not show the same benefit as it does for women 
established on haemodialysis prior to pregnancy, with no significant residual 
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function. Meta-analysis data demonstrating improved outcomes with intensification 
of dialysis do not include women starting dialysis after 20 weeks so should not be 
generalised [5]. In a study of intensive dialysis in pregnancy, a subgroup analysis of 
17 women commencing haemodialysis after conception found no difference in 
gestational age at delivery between those receiving 33±6 hours/week (n=4) 
compared to 15±4h/week (n=13) [28]. In the absence of benefit to pregnancy 
outcome, it is therefore important to consider the potential disadvantages of 
intensive dialysis in pregnancy including treatment burden and accelerated decline 
in residual function [33]. Despite increasing recognition that dialysis in pregnancy 
should be adjusted to residual renal function [16], validated methods for the 
assessment of residual renal function in pregnancy do not exist.  
 
Whether the initiation and prescription of dialysis in pregnancy based on serum urea 
concentration or alternative measures of urinary clearance can optimise pregnancy 
outcome remains unknown. In the absence of better evidence, current expert 
consensus advises that commencement of dialysis in pregnancy is informed urea 
concentration in combination with the trajectory of renal function decline, fluid 
balance, blood pressure control and gestation [36). The risks of commencing dialysis 
in pregnancy should be weighed against those of preterm delivery, especially after 
34 weeks gestation when there is a recognised reduction in risk to the neonate [36]. 
 
Peritoneal dialysis and pregnancy 
The incidence of pregnancy is lower for women on peritoneal dialysis compared to 
haemodialysis (see: Fertility and dialysis). However, successful pregnancies on 
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peritoneal dialysis are described. Batarse et al. (2015) examined outcomes in 47 
pregnant women treated with peritoneal dialysis in pregnancy. Overall infant 
survival was 77%, at a mean gestation of 33 weeks, with a mean birth weight of 
1755g [61]. Jefferys et al. published a series of 5 patients with early start peritoneal 
dialysis in pregnancy (mean urea concentration of 14.6mmol/L). Median gestation at 
delivery was 35 weeks (range 25-38 weeks), and complications of peritoneal dialysis 
including exit site infection, catheter displacement and peritonitis occurred in 3 of 5 
pregnancies [62]. Systematic review data reveals that, despite comparable rates of 
pre-term delivery, peritoneal dialysis is associated with a higher rate of small-for-
gestational-age infants (67%) compared to haemodialysis (31%)[5]. Although cohort 
size and publication bias may inform these data, this finding has led to the 
hypothesis that placentation could be adversely affected by the mechanics of 
peritoneal dialysis.  
 
Peritoneal dialysis offers potential benefits for pregnancy including continuous 
ultrafiltration, avoidance of haemodynamic fluctuation, and no requirement for 
anticoagulation at the time of delivery. However, progressive distension of the 
uterus may necessitate reduced dialysate volumes and affect catheter position 
leading to concern about the capacity to intensify dialysis requirements in 
pregnancy. The supplementation of peritoneal dialysis with intermittent 
haemodialysis in order to augment clearance is described [63].  
The choice of dialysis modality in pregnancy should be informed by availability, 
current and anticipated dialysis efficiency, residual renal function, gestation, 
infection risk, and patient choice.  
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Summary 
Pregnancy rates in women on dialysis have increased and the effects of end-stage 
renal disease on fertility may be reversed by intensified dialysis. Contraceptive and 
pre-pregnancy counselling are therefore required for women on dialysis. Lower risk 
reproductive options including the likelihood of pregnancy following transplantation 
should be considered. All women on dialysis in pregnancy should be managed by an 
experienced, multidisciplinary team.  
 
There is an association between increased dialysis time and improved neonatal 
outcomes for women on dialysis prior to pregnancy. Intensification of dialysis can be 
achieved by an increased in dialysis time and the use of pre-dialysis urea targets. 
Current recommendations include haemodialysis for >36h/week [36,38] and a target 
pre-dialysis urea <12.5mmol/L [30].  
 
There is an increased risk of pre-eclampsia, the development of which is a key 
determinant of pregnancy outcome. Diagnosis of superimposed pre-eclampsia is 
complex with no diagnostic criteria. There is emerging evidence that circulating 
concentrations of PlGF and sFlt-1 have diagnostic utility, although validation in 
dialysis cohorts is required.  
 
For women with advanced progressive CKD, dialysis in pregnancy is usually 
commenced due to the fetotoxicity of urea, rather than for maternal indications. 
Residual renal function contributes to clearance and evidence that dialysis should be 
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intensified in the same way as for women established on dialysis prior to pregnancy 
does not exist. The concentration of urea at which it is beneficial to provide dialysis 
in pregnancy remains unknown.  
 
Limited published data on peritoneal dialysis suggest there may be modality specific 
adverse effects on fertility and fetal growth and intensification dialysis may be 
harder to achieve.  
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Research agenda 
• Standardisation of data collection from pregnant cohorts and the establishment 
of multicentre research groups to allow prospective, large cohort analysis of 
factors contributing to pregnancy outcomes in women on dialysis including 
maternal urea concentration, residual renal function, dialysis modality, renal 
disease aetiology, blood pressure, maternal haemoglobin and cervical length. 
 
• The validation of angiogenic (PlGF) and antiangiogenic (sFlt-1) biomarkers in the 
prediction and diagnosis of pre-eclampsia in women on dialysis. 
 
• Qualitative evaluation of methods used to communicate risk in pregnancy in order to 
increase the understanding of risk and facilitate shared decision-making in reproductive 
health.  
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Table 1: Summary of published literature examining dialysis provision and outcomes 
in pregnancy. Studies included in systematic reviews [5, 64] are not listed separately 
with the exception of [28], which is an important comparative cohort study of 
intensive dialysis in pregnancy. Values are mean unless otherwise stated.   
 
HD=haemodialysis, PD=peritoneal dialysis, IUGR=intrauterine growth restriction, 
SGA=small for gestational age, T1=first trimester, T2=second trimester, T3=third 
trimester 
 
Study Study details 
Number of 
pregnancies 
Dialysis details 
Live birth 
rate/neonatal 
survival 
Hypertension/ 
Pre-eclampsia 
Gestation Birthweight 
Souqiyyeh 
et al.1992 
[23] 
Questionnaire 
(Saudi Arabia) 
27 HD Longer dialysis in 
pregnancies >28 
weeks gestation 
37%  74% <34 
weeks 
 
Hou 1994 
[65] 
Questionnaire 
(US) 
19 Not available 37% overall, 
52% after 1990. 
 95% preterm  
Bagon et al. 
1998[24] 
National survey 
(Belgium) 
15 HD Correlation 
between birth 
weight and dialysis 
dose 
50% for 
established HD, 
80% if new HD 
in pregnancy 
 100% preterm 100% low 
birthweight 
Okundaye 
et al. 1998 
[25] 
Questionnaire 
(US) 
245 HD 
59 PD 
40 unknown 
Trend to better 
survival with 
dialysis >20h/week 
42%  79% >140/90 
48% >170/110 
32.4 weeks,  
84% <37 
weeks 
28% ≤10
th
 centile 
Romão et 
al. 1998 [66] 
Retrospective 
cohort (Brazil) 
14 HD 
3 PD 
HD 15-18h/week, 
PD 6 x 2L/day 
Mean urea 
28mmol/L 
79% HD 
33% PD 
47% 32.3 weeks 1401g 
Toma et al. 
1999 [37] 
Questionnaire 
(Japan) 
74 HD Target urea 
<21mmol/L,  
mean 22h/week 
49%  Severe 
hypertension 
42% 
31.9 weeks 
87% <37 
weeks 
1544g 
93% <2500g 
31% <1000g 
Asamiya et 
al., 2009 
[27] 
 
Retrospective 
cohort (Japan) 
28 HD Mean HD time:- 
• T1: 12.7h/week  
• T2: 15.9h/week 
• T3: 18.4h/week 
Negative 
correlation 
between BW and 
urea 
64% Hypertension 
39% 
92% preterm 42% small for 
dates 
Piccoli et al. 
2014 [64] 
Systematic 
review of 
published 
literature 2000-
2008  
90 
86 HD 
4 PD 
HD 15-40h/week 76%  20-66% 
depending on 
study definition 
67-100% 
preterm 
1390-2418g 
14-80% IUGR 
Piccoli et al. 
2016 [5] 
Systematic 
review of 
published 
literature 2000-
2014, extension 
of [63] 
35 HD start 
after 
conception 
58 
conception 
after HD 
start 
14 PD 
HD: 18-36h/week 
PD: 5-6 x 1.5L  
82% Hypertension 
48-63% 
Pre-eclampsia 
5-14% 
HD: 33 weeks 
PD: 34 weeks 
Conception 
before HD: 1804g, 
SGA 17% 
 
HD before 
conception: 
1700g, SGA 33% 
 
PD: 1780g, SGA 
57% 
Hladunewic
h et al. 2014 
[28] 
Retrospective 
cohort 
comparison of 
intensive 
22 intensive 
HD 
70 
conventiona
Intensive HD: 
43±6h/week 
Conventional HD: 
17±5h/week 
Intensive HD: 
86% 
Conventional 
HD: 61% 
Intensive HD: 
Pre-eclampsia 
5%, severe 
hypertension 
Intensive HD: 
36 weeks 
Conventional  
HD: 27 weeks 
Intensive HD: 
2118g 
Conventional HD: 
1748g 
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(Canada) and 
conventional 
HD (US) 
l HD 
 
Dailysis intensity 
correlates with 
birth rate and 
gestation 
5%.  
Jesudson et 
al. 2014 [60] 
 
Retrospective 
cohort 
(Australia and 
New Zealand)  
63  
22 
conceived 
before 
dialysis, 41 
conceptions 
on dialysis 
(34 HD, 7 
PD) 
Not available  73% (82% after 
20 weeks 
gestation) 
Not available 34 weeks 
(median) 
50% ≤10
th
 
centile 
11% <28 
weeks 
1750g (median) 
Sachdeva et 
al. 2017 [29] 
Internet based 
survey of 
practice (USA) 
187  Most common 
prescription 24-
27h/week. 66% aim 
for pre-dailysis urea 
<17.9mmol/L. More 
live births with 
dialysis >20h/week 
 
78% Pre-eclampsia 
44% 
  
Luders et al. 
2018 [30] 
Retrospective 
cohort (Brazil), 
extension of 
previously 
published data 
[67] 
93 2000-2008: 9-
18h/week 
depending on urine 
output, > or < 1year 
of HD, and body 
weight.  
2009-2017: Target 
midweek urea 
<12.5mmol/L 
89% Pre-eclampsia 
14% 
35 weeks 1689g 
SGA: 48% 
Normand et 
al. [68] 
Retrospective 
cohort (France) 
100 Mean HD time: 
• T1 14.6h/week 
• T3 20.5h/week 
Mean urea: 
• T1 17.0mmol/L 
• T2 13.4mmol/L 
78% 18.8% 33.2 weeks 1719g 
45% <10
th
 centile 
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Table 2: Pre-pregnancy counselling in women on dialysis: modifiable risk factors in 
advance of pregnancy 
 
Factor Details 
Medication • Substitute angiotensin blockade (ACEi/ARB) in advance of pregnancy if 
used for hypertension. Continue angiotensin blockade until conception 
for cardiac indications with regular pregnancy testing during attempts to 
conceive.  
• Stop mycophenolate 6 weeks in advance of pregnancy, substitute with 
azathioprine and ensure disease control before attempts to conceive.  
• Stop statins.  
Blood pressure  • Aim for BP<140/90 on pregnancy safe medications: labetalol, nifedipine, 
methyldopa.  
• Limited published safety data on amlodipine.  
Supplements • Folate: 5mg daily for ≥12 weeks prior to conception for fetal neural tube 
formation. Higher dose recommended due to increased loses with both 
HD and PD [69].  
• Vitamin D: treat deficiency  
Co-existing 
conditions 
• Diabetes: pre-pregnancy HbA1c is associated with pregnancy 
complications. Aim for fasting blood glucose <7mmol/L, HbA1c 
<48mmol/mol (6.5%) but avoid problematic hypoglycaemia. 
• Lupus: quiescent disease for 6 months prior to pregnancy.  
• Genetic counselling for inherited conditions. 
Other • Weight reduction for increased BMI 
• Confirm rubella immunity and vaccinate in advance of pregnancy if 
required 
• Stop smoking 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 3: Obstetric management of women on dialysis [36] [38] should occur in addition to 
standard obstetric care including anomaly screening, lifestyle advice, vaccination, delivery and 
breastfeeding information, mental health screening and support.    
 
Pregnancy stage Management  Additional information 
All Individualised care plan, manage 
as high-risk. 
Coordination of appointments with times on dialysis 
Target blood pressure 
<140/90mmHg (post-dialysis) 
Blood pressure may vary according to fluid state between 
dialysis sessions. Avoid hypotension (<120/70mmHg) on 
dialysis.  
Early Early referral for consultant-led 
care 
Surveillance and management should occur in the context 
of an expert multidisciplinary team.  
Pre-eclampsia prophylaxis with 
low dose aspirin (75-150mg) 
High quality data for high-risk women in general obstetric 
population. [47] [46] 
Pre-eclampsia prophylaxis with 
calcium supplementation 
Indicated for women with calcium deficiency [70], 
although this likely to have been managed in advance of 
pregnancy in women known to nephrology services. 
Supplementation should be limited to 1.5g/day in women 
on dialysis as per CKD guidelines.  
Trisomy screening No increased trisomy risk associated with CKD and 
dialysis. Elevation of β-HCG and PAPP-A in CKD may lead 
to false results. Consider non-invasive testing based on 
circulating fetal DNA if available.   
Folate supplementation  Increased prophylactic dose (5mg daily) due to increased 
losses on dialysis.  
Middle Increased fetal surveillance No outcome data related to different schedules of care. 
Expert consensus: fetal growth and well-being assessment 
at least every 4 weeks from 24 weeks, with more frequent 
assessment if clinically indicated including slowed growth 
trajectory, waveform abnormalities, any clinical concern 
regarding possible superimposed pre-eclampsia.  
Cervical length Increased rates of cervical shortening (18%) in recent 
published cohort of women on dialysis [28]. Significance 
and role of cerclage unknown.  
End Magnesium Maintenance doses given for eclampsia 
prophylaxis/treatment or fetal neuroprotection should be 
omitted or reduced. Monitor for toxicity.  
Delivery Timing of delivery is based on maternal and fetal 
wellbeing. Elective induction of labour may be considered 
at 37 weeks to allow for planning of dialysis and the need 
for anticoagulation around delivery. Vaginal delivery is 
preferred in the absence of obstetric indications for 
Caesarean delivery.   
Post-partum  Contraception Safe and effective contraception should be offered: 
progesterone-only pill, intrauterine device, progesterone 
implant.  
Breast-feeding  Breast-feeding should be encouraged and supported. 
Prescribed medication should be compatible with 
lactation (see 
https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm).  
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On–going renal replacement 
therapy 
Dialysis regimens should accommodate breastfeeding. 
The decision to (re)activate on transplant lists should be 
collaborative.  Consider:  
• transplant immunosuppression may not be 
compatible with lactation  
• balance between neonatal/family commitments and 
the required time in hospital should a transplant 
become available.  
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Highlights 
• Women on dialysis should be offered contraceptive and pre-pregnancy 
counselling 
• Women on dialysis have a high-risk of adverse pregnancy outcomes 
• Intensification of dialysis is associated with improved pregnancy outcomes for 
women who are established on dialysis prior to pregnancy 
• Urea is fetotoxic but the optimum threshold at which dialysis should start in 
pregnancy is not known.  
• Multidisciplinary, collaborative expertise is important in the management of all 
women on dialysis in pregnancy.  
 
